[Development of HIV vaccines].
An effective prophylactic vaccine should reduce frequency of new HIV infections in the target population and delay onset of immunodeficiency among those who become infected after vaccination. A variety of vaccine candidates have been developed, which induce neutralizing antibodies and/or cytotoxic T-lymphocytes. While many of those vaccine candidates exhibited some efficacy in primate model systems, their efficacy against natural HIV-1 infection can only be determined in large-scale phase III clinical trials. In this article, difficulties in HIV vaccine development will be discussed from scientific, technical, and business point of views.
Shibata
Riri
R
D016915:AIDS Vaccines; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000818:Animals; D002986:Clinical Trials as Topic; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120